...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
【24h】

Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.

机译：ST段抬高型心肌梗死患者接受替罗非班辅助双推注方案进行主要经皮冠状动脉介入治疗的血管造影和临床结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Because of different dosages, the efficacy of adjunctive tirofiban therapy for primary percutaneous coronary intervention (PCI) is currently unclear. The hypothesis that a double bolus regimen of tirofiban will improve angiographic and clinical outcomes in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing PCI was tested in the present study. METHODS AND RESULTS: Primary PCI was performed in 217 STEMI patients: 80 received standard PCI (control group) and 137 received tirofiban (tirofiban group). Tirofiban was given as a bolus (10 mg/kg) in the emergency room and again upon arrival at the cardiac catheterization laboratory, followed by infusion of 0.15 mg . kg(-1) . min (-1) until the total dose reached 12.5 mg. The primary endpoint was emergency target vessel revascularization, recurrent myocardial infarction, or cardiovascular mortality at 30 days and 1 year. Baseline clinical and angiographic variables of the 2 groups were similar, as were angiographic results after PCI and bleeding complications at 30 days. The primary 30-day and 1-year endpoints were 5.1% and 11.7% in the tirofiban group, respectively, vs 10.0% (p = 0.171) and 18.8% (p = 0.151) in the control group. CONCLUSION: Although angiographic and clinical benefits were not demonstrated, the results suggest that research into an effective and uniform dosing regimen of adjunctive tirofiban therapy for PCI is warranted.
机译：背景：由于剂量不同，替罗非班辅助治疗在原发性经皮冠状动脉介入治疗（PCI）中的疗效目前尚不清楚。在本研究中，对替罗非班双重推注方案可改善接受PCI的ST段抬高的急性心肌梗死（STEMI）患者的血管造影和临床结局的假设进行了验证。方法和结果：217例STEMI患者进行了原发性PCI：80例接受标准PCI（对照组），137例接受替罗非班（替罗非班组）。替罗非班在急诊室以大剂量（10 mg / kg）的剂量给药，到达心脏导管实验室后再次给药，然后输注0.15 mg。千克（-1）分钟（-1）直至总剂量达到12.5 mg。主要终点为紧急目标血管血运重建，复发性心肌梗塞或30天和1年时的心血管死亡率。两组的基线临床和血管造影变量相似，PCI和30天出血并发症后的血管造影结果也相似。替罗非班组的主要30天和1年终点分别为5.1％和11.7％，而对照组为10.0％（p = 0.171）和18.8％（p = 0.151）。结论：尽管未显示血管造影和临床益处，但结果表明，有必要对替罗非班辅助治疗PCI的有效，统一剂量方案进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号